BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6665765)

  • 1. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs.
    Hilliker KS; Bell TG; Roth RA
    Thromb Haemost; 1983 Dec; 50(4):844-7. PubMed ID: 6665765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE; Sprugel KH; Hadley KB; Roth RA
    J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased vascular responsiveness in lungs of rats with pulmonary hypertension induced by monocrotaline pyrrole.
    Hilliker KS; Roth RA
    Am Rev Respir Dis; 1985 Jan; 131(1):46-50. PubMed ID: 3966714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
    Hilliker KS; Bell TG; Lorimer D; Roth RA
    Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole.
    Ganey PE; Roth RA
    Toxicol Appl Pharmacol; 1987 Apr; 88(2):157-64. PubMed ID: 3564035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of monocrotaline and monocrotaline pyrrole on 5-hydroxytryptamine and paraquat uptake by lung slices.
    Hilliker KS; Garcia CM; Roth RA
    Res Commun Chem Pathol Pharmacol; 1983 May; 40(2):179-97. PubMed ID: 6410470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Ketoprostaglandin F1 alpha and thromboxane B2 in isolated, blood-perfused lungs from monocrotaline pyrrole-treated rats.
    Ganey PE; Roth RA
    J Toxicol Environ Health; 1988; 23(1):127-37. PubMed ID: 3336057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia.
    Ganey PE; Sprugel KH; White SM; Wagner JG; Roth RA
    Am J Physiol; 1988 Nov; 255(5 Pt 2):H1165-72. PubMed ID: 3189578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
    White SM; Wagner JG; Roth RA
    Toxicol Appl Pharmacol; 1989 Jun; 99(2):302-13. PubMed ID: 2734793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
    Bruner LH; Johnson K; Carpenter LJ; Roth RA
    J Toxicol Environ Health; 1987; 21(1-2):205-17. PubMed ID: 3573071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
    Schultze AE; Roth RA
    Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelets and the puzzles of pulmonary pyrrolizidine poisoning.
    Roth RA; Ganey PE
    Toxicol Appl Pharmacol; 1988 May; 93(3):463-71. PubMed ID: 3130680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension.
    Langleben D; Carvalho AC; Reid LM
    Am Rev Respir Dis; 1986 May; 133(5):789-91. PubMed ID: 3085563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats.
    White SM; Roth RA
    Toxicol Appl Pharmacol; 1988 Dec; 96(3):465-75. PubMed ID: 2974653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-keto prostaglandin F1 alpha and thromboxane B2 in isolated, buffer-perfused lungs from monocrotaline pyrrole-treated rats.
    Ganey PE; Roth RA
    Exp Lung Res; 1987; 12(3):195-206. PubMed ID: 3107969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injury to the isolated, perfused lung by exposure in vitro to monocrotaline pyrrole.
    Hilliker KS; Roth RA
    Exp Lung Res; 1985; 8(4):201-12. PubMed ID: 4043006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactate dehydrogenase activity and isozyme patterns in tissues and bronchoalveolar lavage fluid from rats treated with monocrotaline pyrrole.
    Schultze AE; Gunaga KP; Wagner JG; Hoorn CM; Moorehead WR; Roth RA
    Toxicol Appl Pharmacol; 1994 Jun; 126(2):301-10. PubMed ID: 8209383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE; Wagner JG; Roth RA
    Toxicol Appl Pharmacol; 1991 Jul; 109(3):421-31. PubMed ID: 1830177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension and ECG changes from monocrotaline pyrrole in the rat.
    Bruner LH; Hilliker KS; Roth RA
    Am J Physiol; 1983 Aug; 245(2):H300-6. PubMed ID: 6224428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine.
    Pan LC; Wilson DW; Lamé MW; Jones AD; Segall HJ
    Toxicol Appl Pharmacol; 1993 Jan; 118(1):87-97. PubMed ID: 8430429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.